CD58 acts as a tumor promotor in hepatocellular carcinoma via activating the AKT/GSK-3 beta/beta-catenin pathway

Background Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide because of rapid progression and high incidence of metastasis or recurrence. Accumulating evidence shows that CD58-expressing tumor cell is implicated in development of various cancers. The present study aimed to reveal the functional significance of CD58 in HCC progression and the underlying mechanisms. Methods Immunohistochemical staining (IHC), and western blotting were used to detect the expression of CD58 in HCC tissues and cells. The levels of sCD58 (a soluble form of CD58) in the cell supernatants and serum were assessed by ELISA. CCK-8, colony formation, and xenograft assays were used to detect the function of CD58 on proliferation in vitro and in vivo. Transwell assay and sphere formation assay were performed to evaluate the effect of CD58 and sCD58 on metastasis and self-renewal ability of HCC cells. Western blotting, immunofluorescence (IF), TOP/FOP Flash reporter assay, and subcellular fractionation assay were conducted to investigate the molecular regulation between CD58/sCD58 and AKT/GSK-3 beta/beta-catenin axis in HCC cells. Results CD58 was significantly upregulated in HCC tissues. Elevation of CD58 expression correlated with more satellite foci and vascular invasion, and poorer tumor-free and overall survival in HCC patients. Higher sCD58 levels were in HCC patients' serum compared to healthy individuals. Functionally, CD58 promotes the proliferation of HCC cells in vitro and in vivo. Meanwhile, CD58 and sCD58 induce metastasis, self-renewal and pluripotency in HCC cells in vitro. Mechanistically, CD58 activates the AKT/GSK-3 beta/beta-catenin signaling pathway by increasing phosphorylation of AKT or GSK3 beta signaling, promoting expression of Wnt/beta-catenin target proteins and TCF/LEF-mediated transcriptional activity. Furthermore, AKT activator SC-79 or inhibitor LY294002 abolished the inhibitory effect of CD58 silencing on the proliferation, metastasis, and stemness of HCC cells. Conclusions Taken together, CD58 promotes HCC progression and metastasis via activating the AKT/GSK-3 beta/beta catenin pathway, suggesting that CD58 is a novel prognostic biomarker and therapeutic target for HCC.

Automated summary

CD58 is upregulated in HCC tissues and its overexpression is associated with poor prognosis in HCC patients. CD58 promotes proliferation and metastasis in HCC cells by activating the AKT/GSK-3β/β-catenin pathway, suggesting that CD58 may serve as a prognostic biomarker and therapeutic target for HCC.